A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Public ClinicalTrials.gov record NCT06454240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups. The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.
Study identification
- NCT ID
- NCT06454240
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2024 (Actual)
- Primary completion
- Jan 29, 2026 (Actual)
- Completion
- Apr 23, 2026 (Actual)
- Last update posted
- Apr 28, 2026
2024 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Allergy & Rheumatology- Site Number : 8400005 | La Jolla | California | 92037 | — |
| Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003 | Roseville | California | 95661 | — |
| Senta Clinic- Site Number : 8400025 | San Diego | California | 92018 | — |
| James A Haley Veterans' Hospital- Site Number : 8400015 | Tampa | Florida | 33612 | — |
| Emory University Hospital Midtown- Site Number : 8400012 | Atlanta | Georgia | 30308 | — |
| The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002 | Boise | Idaho | 83706 | — |
| Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016 | Boston | Massachusetts | 02115 | — |
| Essential Medical Research- Site Number : 8400020 | Tulsa | Oklahoma | 74137 | — |
| McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 | Bellaire | Texas | 77401 | — |
| Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004 | Dallas | Texas | 75231 | — |
| Berkson Medical - McKinney- Site Number : 8400014 | McKinney | Texas | 75070 | — |
| Alamo ENT Associates Site Number : 8400001 | San Antonio | Texas | 78258 | — |
| Advanced Research Institute - Odgen- Site Number : 8400022 | Ogden | Utah | 84405 | — |
| Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008 | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06454240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06454240 live on ClinicalTrials.gov.